Five outstanding young Chinese scholars received the Third Scholar Award from the Asian Fund for Cancer Research (AFCR) and the US Chinese Anti-Cancer Association (USCACA)

Abstract

Chinese researchers and physicians are being increasingly recognized for making significant contributions that advance biomedical research, including cancer research, in both China and the world. To facilitate and strengthen collaborations among cancer researchers and physicians in the United States and China, the US Chinese Anti-Cancer Association (USCACA) and the US National Foundation for Cancer Research (USNFCR) have established the Scholar Excellence Award for the USNFCR-USCACA Scholar Exchange and Fellowship Program in Basic, Translational, and Clinical Studies. Since 2010, 5 young Chinese researchers and physicians have received the Scholar Excellence Award for their outstanding achievements in cancer research performed while in the United States, as well as their continuous contributions to eradicate cancer after their return to China. This year, the USCACA joined the Asian Fund for Cancer Research, Ltd. (AFCR) in selecting 5 promising individuals for their excellence in basic or clinical cancer research. Here, we are proud to introduce the 5 winners of the 2012 AFCR-USCACA Scholar Excellence Award: Dr. Xiuli Bi at the College of Life Science, Liaoning University, Shenyang; Dr. Binghui Li in the Laboratory of Cancer Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Dr. Lina Zhang in the Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Dr. Yi Zhang in the Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu; Dr. Yuhua Zhao in the Department of Biochemistry and Molecular Biology, Sichuan University, Chengdu, Sichuan. We have invited these awardees to contribute a short essay that summarizes their achievements in cancer research. As illustrated in their essays, these outstanding young scholars have received excellent training under their US mentors. They have not only made impressive discoveries in the mechanisms underlying the causes or progression of human cancers but also discovered new approaches for improving treatment for cancer patients. Our ultimate goal is to expedite novel cancer drug development by stimulating the translation of lab discoveries into novel cancer treatments, fostering collaborations in clinical cancer drug development, and sharing expert knowledge and medical practices between China and the United States.